These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29689643)

  • 21. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
    Zhang PF; Li KS; Shen YH; Gao PT; Dong ZR; Cai JB; Zhang C; Huang XY; Tian MX; Hu ZQ; Gao DM; Fan J; Ke AW; Shi GM
    Cell Death Dis; 2016 Apr; 7(4):e2201. PubMed ID: 27100895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.
    Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH
    Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
    Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
    PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
    Liu T; Wu X; Li Y; Lu W; Zheng F; Zhang C; Long Q; Qiu H; Li Y; Ge Q; Chen M; Yu X; Chen W; Zhang H; Huang W; Luo M; Deng W; Li L
    Cell Physiol Biochem; 2018; 46(4):1365-1380. PubMed ID: 29689552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment.
    Li Q; Ma L; Shen S; Guo Y; Cao Q; Cai X; Feng J; Yan Y; Hu T; Luo S; Zhou L; Peng B; Yang Z; Hua Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):303. PubMed ID: 31296243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway.
    Huang T; Chen QF; Chang BY; Shen LJ; Li W; Wu PH; Fan WJ
    Dis Markers; 2019; 2019():7129214. PubMed ID: 31281549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma.
    Chen JS; Li HS; Huang JQ; Dong SH; Huang ZJ; Yi W; Zhan GF; Feng JT; Sun JC; Huang XH
    Cancer Lett; 2016 May; 375(1):73-83. PubMed ID: 26944318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.
    Li J; Lau GK; Chen L; Dong SS; Lan HY; Huang XR; Li Y; Luk JM; Yuan YF; Guan XY
    PLoS One; 2011; 6(7):e21816. PubMed ID: 21760911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced myeloid differentiation factor 88 promotes tumor metastasis via induction of epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Jia RJ; Cao L; Zhang L; Jing W; Chen R; Zhu MH; Guo SW; Wu GB; Fan XY; Wang H; Zhang YY; Zhou XY; Zhao J; Guo YJ
    Cell Death Dis; 2014 Mar; 5(3):e1103. PubMed ID: 24603331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
    Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
    Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
    Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
    Ying D; Ruan Y; Zhou X
    Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells.
    Dong Y; Wu Z; He M; Chen Y; Chen Y; Shen X; Zhao X; Zhang L; Yuan B; Zeng Z
    Cancer Lett; 2018 May; 421():1-14. PubMed ID: 29432845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
    J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling.
    Liu Z; Chen M; Xie LK; Liu T; Zou ZW; Li Y; Chen P; Peng X; Ma C; Zhang WJ; Li PD
    Aging (Albany NY); 2018 Oct; 10(10):2570-2584. PubMed ID: 30312171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.